The Division for Advancement and External Relations  

Status : ACTIVE Birth place : JERUSALEM
Office Phone: 02-675-7515 Fax: 02-643-0834
Department Faculty  
Academic Degree   Institution Year
Academic Position   Year
External Academic Positions and Awards
Post-doctoral studies, Dept. of Molec. & Cellular Biol.,
Harvard Univ., 1995-99.
Rothschild Fellowship, 1995-6; Fulbright Fellowship, 1995-6;
EMBO Long Term Fellowship, 1995-97; Fellowship, Cancer Res.
Fund, Damon Runyon-Walter Winchell Foundation, 1997-2000;
Alon Fellowship, 2000-03.
Awards: Kaye Innovation Award at The Hebrew Univ., 2015.
Member, Israeli Soc. of Immunology; Am. Soc. of Immunology.
Research Interests
Development of novel approaches for cancer therapy.
Molecular immunology of human NK cells. Studying NK cell functions during
pregnancy. Studying the involvement of NK cells during viral infections.
Development of knockout mice models for studying NK functions.
Research Projects
Recognition of viruses and tumors by NK cells.
The function of NK cells during pregnancy.
Modulation of NK activity by microRNA.
The molecular mechanism controlling the interactions between members
NK defense and therapy. (Coordinator: Dr. Erhard Hufer).
Anti-tumor targeting. (Coordinator: Dr. Erhard Hufer).
TAP2-deficiency and tumors.
Tumor development in the absence of the NK activating receptor Ncr1.
Tumor development in the absence of NK activating receptors.
Killing of pathogens in the absence of NCR1.
Identification of cellular microRNAs controlling the function of
Eradication of lymphomas by the NK killer receptor NKp46.
Killing of pathogens in the absence of NCR1.
Killing of beta cells by the NK killer receptor NKp46.
The function of Natural Killer cells in TAP-2 deficient patients.
The function of the NK killer receptor NKp46 in CMV and influenza
Regulation and function of viral and cellular microRNAs controlling
Identifying microRNA-based tumor immunoevasion mechanisms through the
Selected Publications
Publication Title   Year
The expression of the beta cell-derived autoimmune ligand for 2013
The unique properties of uterine NK cells. [Epub 2010 Jan 4]. 2010
Tumor immunoediting by NKp46. [Epub 2010 Apr 19]. 2010
Killing of avian and swine influenza virus by natural killer 2010
The activating receptor NKp46 is essential for the development 2010
Methods to identify and characterize different NK cell receptors 2010
Notch activation enhances IFNgamma secretion by human peripheral 2010
Analysis of human cytomegalovirus-encoded microRNA activity 2009
The interaction of TIGIT with PVR and PVRL2 inhibits human NK 2009
Dynamic behavior of NK cells during activation in lymph nodes. 2009
An integrated view of the regulation of NKG2D ligands (Review). 2009
Diverse herpesvirus microRNAs target the stress-induced immune 2009
Enhanced in vivo growth of lymphoma tumors in the absence of the 2009
Microbial flora drives interleukin 22 production in intestinal 2008
Human microRNAs regulate stress-induced immune responses 2008
Immunological assessment of familial tinea corporis. 2008
Altered glycosylation of recombinant NKp30 hampers binding to 2008
Endometrial NK cells are special immature cells that await 2008
Influenza virus infection augments NK cell inhibition through 2008
Manipulation of NK cytotoxicity by the IAP family member Livin. 2007
A phenotypic and functional characterization of NK cells in 2007
Neisserial outer membrane vesicles bind the co-inhibitory 2007
Host immune system gene targeting by a viral miRNA. 2007
Subcellular localization determines the delicate balance between 2007
HLA-G complexes are observed on the cell surface. 2007
CD100 on NK cells enhance IFNgamma secretion and killing of 2007
Reduced KIR2DL1 recognition of MHC class I molecules presenting 2006
Lethal influenza infection in the absence of the natural killer 2006
Human embryonic stem cells and their differentiated derivatives 2006
CEACAM1 (CD66a) promotes human monocyte survival via a 2006
Inhibition of human tumor-infiltrating lymphocyte effector 2006
Decidual NK cells regulate key developmental processes at the 2006
Functional aberrant expression of CCR2 receptor on chronically 2005
The CD85J/leukocyte inhibitory receptor-1 distinguishes between 2005
The involvement of NK cells in ankylosing spondylitis. 2005
Carcinoembryonic antigen (CEA) inhibits NK killing via 2005
Inhibition of the NKp30 activating receptor by pp65 of human 2005
Maternal adaptation to vasculogenesis and angiogenesis at the 2005
2B4 (CD244) is expressed and functional on human eosinophils. 2005
Novel insights on human NK cells' immunological modalities 2004
The critical role of residues 43R and 44Q of carcinoembryonic 2004
Biological function of the soluble CEACAM1 protein and 2004
Involvement of the CXCL12/CXCR4 pathway in the advanced liver 2004
Caspase-mediated cleavage converts Livin from an antiapoptotic 2003
CXCL12 expression by invasive trophoblasts induces the specific 2003
Complexes of HLA-G protein on the cell surface are important for 2003
Enhanced recognition of human NK receptors after influenza virus 2003
Involvement of CXCR4 and IL-2 in the homing and retention of 2003
Pivotal role of CEACAM1 protein in the inhibition of activated 2002
Expression of CD66a (CEACAM1) on human melanoma and NK cells: A 2002
Recruitment of MHC class I molecules by Tapasin into the 2002
Characterization of the major histocompatibility complex 2002
The NKp46 receptor contributes to NK cell lysis of mononuclear 2002
Recognition of haemagglutinins on virus-infected cells by NKp46 2001
Recognition of viral hemagglutinins by NKp44 but not by NKp30. 2001
Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor 2001
N-linked carbohydrate on human leukocyte (HLA)-C and recognition 2000
The human natural killer cell immune synapse. 1999
The selective downregulation of class I major histocompatibility 1999
The transmembrane sequence of human leukocyte antigen (HLA-) C 1999
Patent Name  Year
NK cell activating receptors and their therapeutic and diagnostic 2002


© All rights reserved to The Hebrew University of Jerusalem